Frontal fibrosing alopecia developing after hair transplantation for androgenetic alopecia

Skin and Cancer Foundation Australia, Darlinghurst, NSW 2010, Australia.
International Journal of Dermatology (Impact Factor: 1.23). 05/2005; 44(4):321-3. DOI: 10.1111/j.1365-4632.2004.02251.x
Source: PubMed
  • Source
    • "Frontal fibrosing alopecia (FFA) in an entity characterized by the recession of the frontotemporal hairline (FTHL) with alopecic scarring changes, usually accompanied by alopecia in other non-scalp locations. Initially defined as a disease appearing only in postmenopausal women, no hormonal status association was later proven.[1] However, the rest of FFA clinical manifestations such as axillar or eyebrow alopecia, lichen planopilaris, or pruritus appear in a variable frequency, except for the mentioned recession of the hairline present in all patients.[2] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Frontal fibrosing alopecia (FFA) in an entity characterized by the recession of the frontotemporal hairline (FTHL) with alopecic scarring change. In recent years there are numerous articles discussing the usefulness of dermoscopy for the clinical diagnosis of different types of scarring alopecia. We value 79 patients diagnosed with FFA, evaluating some trichoscopical findings described as typical for FFA: Absence of follicular opening, follicular hyperkeratosis, follicular plugs and erythema. In a population of 79 women, 100% showed no follicular opening, 72.1% follicular hyperkeratosis, 66.3% perifollicular erythema and 44.8% follicular plugs. Thus, 100% of patients had at least one of the dermoscopic elements described as suggestive of FFA, 53% two of them, 45% three and 27%, all those elements. Perifollicular erythema was present in 95% of cases in which the disease was active. We consider that the presence of perifollicular erythema will be a direct marker of FFA activity.
    International Journal of Trichology 07/2013; 5(3):151-3. DOI:10.4103/0974-7753.125616
  • [Show abstract] [Hide abstract]
    ABSTRACT: The in vitro interaction between the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cytoskeletal elements is well documented. To verify this association within cells, the intracellular distribution of GAPDH under various metabolic conditions has been investigated in immunostained cells or cells expressing GAPDH as a GFP fusion protein. GAPDH was homogeneously distributed in the cytoplasm and no interaction of GAPDH with cytoskeletal elements, neither with microfilaments nor microtubules or intermediate filaments, was detectable. In living cells expressing GFP-GAPDH, stress fibres were excluded from the fluorescence. In contrast to proliferating cells, the cytoplasmic GAPDH of serum-depleted cells was not homogeneously distributed, but colocalised with stress fibres. The mechanism for stimulating this actin-binding affinity was independent of the NO-signalling pathway. The results support the idea of a specialised function for the interaction of GAPDH and cytoskeletal elements, rather than a general function, as e.g. microcompartmentalization of glycolytic enzymes.
    Cell Biology International 02/2002; 26(2):155-64. DOI:10.1006/cbir.2001.0819 · 1.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The most common form of hair loss is androgenic alopecia that affects at least half of the male population by age 50 is speculated to be caused by a change in the balance of androgen hormones. Male hair loss occurs in a characteristic pattern of decreased hair growth where hair becomes progressively finer, less pigmented, ceasing growth completely, and then becoming dislodged from the scalp. Hair loss to some patients is a serious issue that can impart a social and psychologic impact on their life. Hair restoration and transplantation have the potential to provide a solution for this problem; however, it is not effective for every patient. This review article looks at past hair transplantation techniques and studies that have provided the basis for current procedures and new research at how to target successful results.
    Dermatologic Therapy 11/2007; 20(6):436-47. DOI:10.1111/j.1529-8019.2007.00159.x · 1.48 Impact Factor
Show more